Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat
Tweet Send to a Friend
Baird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
